Co-Diagnostics

CODX

Market cap $16.1M

Overview Fund Activity

0.4171 USD

-0.2217

34.71%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

0.4107

-0.0064

1.53%

1 day

-34.71%

5 days

32.83%

1 month

30.34%

3 months

54.08%

6 months

-7.72%

Year to date

-42.28%

1 year

-66.9%

5 years

-97.09%

10 years

-92.82%

About: Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Employees: 132

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

2.03% less ownership

Funds ownership: 17.41% [Q1] → 15.38% (-2.03%) [Q2]

8% less funds holding

Funds holding: 38 [Q1] → 35 (-3) [Q2]

20% less capital invested

Capital invested by funds: $1.81M [Q1] → $1.45M (-$360K) [Q2]

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$10

2,298% upside

Avg. target

$10

2,298% upside

High target

$10

2,298% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital

Jason Kolbert

$10

Buy

Maintained

17 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CODX published over the past 30 days

Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

SALT LAKE CITY , Sept. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into a securities purchase agreement with several institutional investors for the purchase and sale of 9,619,000 shares of common stock at an offering price of $0.40 per share, in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering").

Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains

SALT LAKE CITY , Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has performed an in silico analysis of the primers sets used in its Co-Primers®-based PCR tests for the detection of chikungunya virus (or "CHIKV"), showing a high homology against over 1,200 CHIKV sequences and confirming reactivity of the CHIKV primers against known recent strains of the virus.

Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains

Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit

SALT LAKE CITY , Sept. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Co-Dx™ was an honoree at the Utah Business 2025 Innovation Awards Summit for the Co-Dx PCR platform*, in the Healthcare and Life Sciences category.

Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit

Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.

SALT LAKE CITY , Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will be hosting a booth at the 17th Annual Next Generation Dx Summit, held virtually and in-person at the Capital Hilton in Washington, D.C. on August 18-20, 2025.

Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.

Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2025 Earnings Conference August 14, 2025 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Brian L. Brown - CFO & Company Secretary Dwight H.

Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript

Zacks Investment Research

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.25 per share a year ago.

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates

Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results

SALT LAKE CITY , Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Results: Revenue of $0.2 million, which declined from $2.7 million during Q2 2024 primarily due to timing of grant revenue recognition.

Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results

Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast

SALT LAKE CITY , July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast

Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025

SALT LAKE CITY , July 15, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at WHX (World Health Expo) Kuala Lumpur on July 16-18, 2025, at the Malaysia International Trade and Exhibition Centre (MITEC). WHX Kuala Lumpur, formerly Asia Health/Medlab Asia, is the leading healthcare exhibition in Southeast Asia, providing networking and collaboration opportunities with industry leaders from across the globe.

Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025

Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference

Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City.

Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference

See News Rankings

Charts implemented using Lightweight Charts™